Literature DB >> 991122

Plasma estrogen in patients with endometrial hyperplasia and carcinoma.

F A Aleem, M A Moukhtar, H C Hung, S L Romney.   

Abstract

In a total of 53 patients, most of whom were over 40 years of age and who presented symptoms of vaginal bleeding, total plasma estrogens were measured with gas liquid chromatography, and the clinical correlates were studied. The results revealed that total plasma estrogen levels in the endometrial hyperplasia and endometrial carcinoma groups were significantly higher than those measured in the control group. In addition, a positive, significant correlation was found between the plasma estrogen levels and obesity in the patients with endometrial carcinoma. The study provides objective data that document the clinical impressions that hyperestrogenism and obesity are significant findings in endometrial carcinoma.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 991122     DOI: 10.1002/1097-0142(197611)38:5<2101::aid-cncr2820380537>3.0.co;2-x

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

Review 1.  Recent advances in studies on estrogen biosynthesis.

Authors:  A M Brodie
Journal:  J Endocrinol Invest       Date:  1979 Oct-Dec       Impact factor: 4.256

2.  Clonidine (Dixarit) for menopausal flushing.

Authors:  R F Edington; J P Chagnon; W M Steinberg
Journal:  Can Med Assoc J       Date:  1980-07-05       Impact factor: 8.262

3.  Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study.

Authors:  A Zeleniuch-Jacquotte; A Akhmedkhanov; I Kato; K L Koenig; R E Shore; M Y Kim; M Levitz; K R Mittal; U Raju; S Banerjee; P Toniolo
Journal:  Br J Cancer       Date:  2001-04-06       Impact factor: 7.640

4.  An estrogen-induced endometrial hyperplasia mouse model recapitulating human disease progression and genetic aberrations.

Authors:  Chieh-Hsiang Yang; Aliyah Almomen; Yin Shen Wee; Elke A Jarboe; C Matthew Peterson; Margit M Janát-Amsbury
Journal:  Cancer Med       Date:  2015-03-23       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.